Invivyd Earnings Call Transcripts
Fiscal Year 2026
-
The conference highlighted a robust pipeline of monoclonal antibodies for infectious diseases, with VYD2311 in late-stage development targeting broad COVID-19 prophylaxis. Key programs in RSV, measles, and long COVID are advancing, with commercial and regulatory strategies focused on broadening access and market impact.
-
Monoclonal antibodies are positioned as a disruptive, more natural alternative or complement to vaccines, with pivotal COVID-19 trial data expected in late Q3. The pipeline targets RSV and measles, aiming to improve outcomes for vulnerable populations and reshape public health strategies.
-
The meeting confirmed a quorum, elected six directors for one-year terms, and ratified the independent auditor for 2026. No additional proposals or questions were raised, and forward-looking statements referenced risk factors in the annual report.
-
VYD2311 pivotal trial is progressing well, with strong PEMGARDA sales and a robust cash position. The company is expanding its antibody pipeline and preparing for potential VYD2311 commercialization, while leveraging AI and public education to drive growth.
-
VYD2311, a next-gen COVID-19 monoclonal antibody, is advancing in a pivotal study with expanded enrollment and strong FDA collaboration, while a novel measles antibody, VMS-063, shows high preclinical potency and targets unmet needs amid rising outbreaks. Both programs aim to complement or surpass vaccines for vulnerable populations.
Fiscal Year 2025
-
REVOLUTION clinical program advanced with DECLARATION study reaching target enrollment and positive safety review. Q4 revenues grew 31% sequentially, and strong cash reserves support pivotal VYD2311 data in mid-2026. PEMGARDA adoption and pipeline expansion position the company for broader market impact.
-
The company is advancing 2311, a next-generation intramuscular COVID prevention antibody, into pivotal trials, aiming for FDA submission by mid-2026 and broader patient access at a lower cost. The product offers higher potency, easier administration, and is positioned as a vaccine alternative.
-
Q3 2025 saw strong PEMGARDA revenue growth, a major $87M capital raise, and FDA feedback enabling pivotal VYD2311 studies. The company is well-funded for clinical and commercial expansion, with robust market opportunity as COVID vaccine uptake lags.
-
VYD2311, a next-generation monoclonal antibody, is being advanced as a durable, safe alternative to COVID vaccination, with pivotal studies designed to demonstrate robust protection and favorable safety. The program targets broad populations, leverages strong preclinical and clinical data, and aims for significant commercial impact.
-
The company is advancing monoclonal antibody therapies for viral diseases, with PEMGARDA showing strong commercial uptake and VYD-2311 poised for pivotal trials and easier administration. Pipeline expansion includes RSV and measles, supported by a recent capital raise and a focus on broader market impact.
-
PEMGARDA is currently authorized for COVID-19 prevention in immunocompromised individuals, while VYD2311 is being developed as a broadly accessible, highly effective, and durable alternative to vaccines. Constructive FDA feedback may enable a full BLA for VYD2311, with commercialization plans focused on broad access and rapid scaling.
-
The company is advancing monoclonal antibody programs for COVID-19, RSV, and measles, with strong commercial momentum for PEMGARDA and a next-gen candidate, VYD2311, showing higher potency and new administration routes. Key milestones include 2311 data and pipeline updates by end of 2025.
-
Q1 2025 saw a temporary revenue dip due to the internalization of the sales force, but Q2 shows strong recovery and growth. Operating expenses declined 15% sequentially, and the company targets profitability by mid-2025, supported by a solid cash position and expanded commercial reach.
-
The company is advancing monoclonal antibody therapies for viral diseases, with PEMGARDA showing strong efficacy in COVID-19 prevention and new candidates like VYD2311 targeting broader, more convenient use. Financial performance is improving, with profitability expected by mid-year and expansion into other pathogens like RSV planned.
Fiscal Year 2024
-
Q3 2024 saw strong clinical results for PEMGARDA but commercial setbacks due to FDA and third-party data confusion, leading to withdrawn revenue guidance. Operational efficiencies and a robust cash position support a return to profitability by mid-2025, with next-gen antibody VYD2311 advancing in trials.
-
Pemgarda, a monoclonal antibody for COVID-19 prevention in immunocompromised patients, has shown strong efficacy and activity against major variants, with rapid EUA approval and expanding market uptake. The company is transitioning to an internal sales force, advancing next-generation assets, and expects to reach profitability in the first half of next year.
-
PEMGARDA, a novel antibody for COVID-19 prevention, demonstrated strong efficacy and is targeting a large, high-risk population. The company is advancing next-generation candidates, expanding commercialization, and aims to broaden access while addressing safety and competitive differentiation.
-
Focused on antibody therapies for immunocompromised patients, the company rapidly advanced Pemgarda to EUA and is expanding its reach with a proprietary platform and new pipeline candidates. Strong early sales, robust variant coverage, and a solid cash position support ongoing launches and development.
-
Pemgarda, a monoclonal antibody for COVID-19 prevention in immunocompromised patients, launched after EUA in March 2024, with strong payer coverage and rapid commercial uptake. Next-generation antibody VYD-2311 is in early trials, aiming for broader protection and faster regulatory approval.
-
Leadership transition and operational improvements have driven commercial and pipeline progress, with net revenue growth in Q2 and acceleration into Q3. Major commercial activation is planned for the fall, supported by expanded reimbursement and infusion site access.
-
PEMGARDA launched in April for immunosuppressed patients, with strong early demand and 2024 net revenue guidance of $150–$200 million. The product shows robust efficacy against current variants, and the company expects at least $75 million in year-end cash, with no immediate need for new capital if sales targets are met.